A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [Proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis
A Prospective, Randomized, Double-blind, Parallel-group Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of MB04 and EU-sourced Enbrel® in Patients With Moderate to Severe Rheumatoid Arthritis
A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in rheumatoid arthritis
研究概览
详细说明
The study will randomize approximately 458 patients aged between 18 and 75 years with active Rheumatoid Arthritis despite methotrexate therapy.
All patients shall receive methotrexate for ≥12 weeks and on a stable dose (10 to 25 mg/week) for ≥8 weeks prior to randomization, and folic acid (≥5 mg/week) from 4 weeks prior to screening until the end of the treatment period (Week 36).
Screening evaluations will be completed within 28 days prior to randomization. There will be 2 periods in the study: Main Treatment Period and Transition Period.
During the Main Treatment Period, eligible patients will be randomized, at a 1:1 ratio, to administer a 50 mg weekly dose of MB04 or EU- sourced Enbrel® subcutaneously (SC) using an Interactive Response System (IRT). After completing Week 24 assessment, patients will continue to receive the study treatment up to Week 36. Those patients who were originally assigned to EU-sourced Enbrel® will be randomized, at a 1:1 ratio, to receive either MB04 or EU-sourced Enbrel® SC, while patients originally assigned to MB04 will continue with the same treatment until Week 36.
After treatment discontinuation, patients will undergo a Safety Follow-up Period for 4 weeks, up to Week 40.
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Batumi、乔治亚州
- Research site 7004
-
Batumi、乔治亚州
- Research site 7010
-
Tbilisi、乔治亚州
- Research site 7001
-
Tbilisi、乔治亚州
- Research site 7002
-
Tbilisi、乔治亚州
- Research site 7003
-
Tbilisi、乔治亚州
- Research site 7005
-
Tbilisi、乔治亚州
- Research site 7006
-
Tbilisi、乔治亚州
- Research site 7007
-
Tbilisi、乔治亚州
- Research site 7009
-
-
-
-
-
Haskovo、保加利亚
- Research site 2007
-
Plovdiv、保加利亚
- Research site 2005
-
Rousse、保加利亚
- Research Site 2002
-
Sofia、保加利亚
- Research site 2001
-
Sofia、保加利亚
- Research Site 2003
-
Sofia、保加利亚
- Research Site 2008
-
Vidin、保加利亚
- Research site 2004
-
Vratsa、保加利亚
- Research site 2006
-
-
-
-
-
Belgrade、塞尔维亚
- Research site 1903
-
Belgrade、塞尔维亚
- Research site 1904
-
Belgrade、塞尔维亚
- Research site 1905
-
Novi Sad、塞尔维亚
- Research Site 1902
-
Zrenjanin、塞尔维亚
- Research site 1901
-
-
-
-
-
Chisinau、摩尔多瓦、MD-2068
- Research Site 1301
-
Chisinau、摩尔多瓦、MD2025
- Research site 1302
-
Chisinau、摩尔多瓦
- Research site 1303
-
-
-
-
-
Bialystok、波兰
- Research Site 1603
-
Bialystok、波兰
- Research Site 1614
-
Bialystok、波兰
- Research site 1616
-
Bydgoszcz、波兰
- Research site 1613
-
Bytom、波兰
- Research site 1623
-
Elblag、波兰
- Research Site 1615
-
Elblag、波兰
- Research Site 1627
-
Gdynia、波兰
- Research Site 1606
-
Katowice、波兰
- Research Site 1611
-
Krakow、波兰
- Research Site 1617
-
Lublin、波兰
- Research Site 1622
-
Nowa Sól、波兰
- Research site 1605
-
Opole、波兰
- Research Site 1618
-
Piotrkow Trybunalski、波兰
- Research site 1628
-
Poniatowa、波兰
- Research Site 1624
-
Poznan、波兰
- Research Site 1601
-
Poznan、波兰
- Research Site 1602
-
Poznan、波兰
- Research Site 1608
-
Poznan、波兰
- Research Site 1619
-
Poznan、波兰
- Research Site 1621
-
Siedlce、波兰
- Research Site 1612
-
Sochaczew、波兰
- Research Site 1610
-
Stalowa Wola、波兰
- Research site 1629
-
Torun、波兰
- Research Site 1620
-
Warsaw、波兰
- Research Site 1604
-
Warsaw、波兰
- Research Site 1607
-
Warsaw、波兰
- Research Site 1609
-
Wroclaw、波兰
- Research Site 1625
-
Zamość、波兰
- Research Site 1626
-
-
-
-
-
Bacau、罗马尼亚
- Research Site 1803
-
Brasov、罗马尼亚
- Research Site 1805
-
Bucharest、罗马尼亚
- Research Site 1801
-
Bucharest、罗马尼亚
- Research site 1802
-
Bucharest、罗马尼亚
- Research site 1804
-
Râmnicu Vâlcea、罗马尼亚
- Research site 1806
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion
- Documented history of RA diagnosis consistent with the 2010 ACR/EULAR classification criteria ≥6 months prior to randomization (but not exceeding 15 years prior to screening).
- Moderately to severe RA despite appropriate MTX at baseline therapy defined as having more than or equal to six swollen joints and more than or equal to six tender joints and either erythrocyte sedimentation rate (ESR, Westergren) ≥ 28 mm/h or serum C-reactive protein > 5.0 mg/dL and positive rheumatoid factor and/or CCP at screening
- Stable dose MTX between 10 to 25 mg weekly during ≥12 weeks, since ≥8 weeks prior to randomization
- Stable dose of NSAID and/or other analgesics for at least 4 weeks prior to randomization, when used
- Stable dose ≤10 mg prednisone daily or equivalent for ≥4 weeks prior to randomization, when used
- Patients who are otherwise medically stable according to investigator's discretion
- Agree to use highly effective contraceptive methods up to 6 months after last dose Exclusion
- Previously treated with any biologic or targeted synthetic DMARD
- Previously treated with any monoclonal antibody for a condition other than RA
- Hypersensitivity to any component of study drug and/or prefilled syringe components
- Arthritis with onset prior to age 16 years or current diagnosis of inflammatory joint disease other than RA
- Systemic manifestations of RA other than rheumatoid nodules or secondary Sjogren's syndrome
- Active infection or potentially relapsing infections that could have a severe outcome. Latent tuberculosis infection detected during screening should start an approved treatment regimen according to standard of care and rescreened
- Solid or hematologic malignancy within the past 5 years
- Pregnant and breastfeeding women
- Any medical condition in the opinion of the investigator that would be a risk for safety, cooperation in the study or interferes with the interpretation of the study results
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:MB04 (proposed etanercept biosimilar)
MB04 50 mg/week via subcutaneous injection |
MB04 50 mg/week via subcutaneous injection |
|
有源比较器:Enbrel (etanercept)
Enbrel 50 mg/week via subcutaneous injection |
Enbrel 50 mg/week via subcutaneous injection |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
美国风湿病学会 20% 反应标准 (ACR20)
大体时间:第 24 周
|
第 24 周
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
ACR20
大体时间:第 36 周
|
第 36 周
|
|
美国风湿病学会 50% 反应标准 (ACR50)
大体时间:第 24 周和第 36 周
|
第 24 周和第 36 周
|
|
美国风湿病学会 70% 反应标准 (ACR70)
大体时间:第 24 周和第 36 周
|
第 24 周和第 36 周
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- MB04-C-01-23
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.